Showing results (31-40 of 606) with videos related to
Sort By:
Pageof 61
Expert Opinion on Investigational Drugs|August 29, 2014
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetesBertrand Cariou, Bart StaelsCurrent Opinion in Lipidology|March 14, 2007
The orphan nuclear receptor Rev-erbalpha: a transcriptional link between circadian rhythmicity and cardiometabolic diseaseCoralie Fontaine, Bart StaelsTrends in Pharmacological Sciences|April 7, 2007
FXR: a promising target for the metabolic syndrome?Bertrand Cariou, Bart StaelsNuclear Receptor Signaling|April 11, 2006
Potential roles of ROR-alpha in cardiovascular endocrinologySaara Laitinen, Bart StaelsTrends in Cardiovascular Medicine|April 26, 2008
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanismsRéjane Paumelle, Bart StaelsCurrent Opinion in Lipidology|October 16, 2009
Combination therapy of statins and fibrates in the management of cardiovascular riskCatherine Fiévet, Bart StaelsJournal of Applied Physiology (Bethesda, Md. : 1985)|August 22, 2009
Rev-erb-alpha: an integrator of circadian rhythms and metabolismHélène Duez, Bart StaelsScientific Reports|November 1, 2017
Rev-erb-α regulates atrophy-related genes to control skeletal muscle massAlicia Mayeuf-Louchart, Quentin Thorel, Stéphane Delhaye, et al.Diabetes|July 28, 2005
Therapeutic roles of peroxisome proliferator-activated receptor agonistsBart Staels, Jean-Charles FruchartDiabetologia|October 4, 2016
An oxidative stress paradox: time for a conceptual change?Joel T Haas, Bart StaelsPageof 61